Gefitinib is a targeted therapy drug used primarily in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of medications known as epidermal growth factor receptor (EGFR) inhibitors. Gefitinib works by inhibiting the tyrosine kinase activity of the EGFR, which is often overexpressed in various cancers, leading to uncontrolled cell growth.
